At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. Skip to Main Content. Manage alerts for this article; ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

ASCO is usually sweltering, but it’s surprisingly chilly today. We’re back with a roundup of tragic paradoxes, a race for new breast cancer drugs, and all that jazz. advertisement.

The panel discussion at the "Breathtaking Moments" event during ASCO weekend. (Johnson & Johnson) Swarner led a discussion with lung cancer survivor Maggie McCloskey, patient advocate and podcast ...

By attending ASCO, he said marketers can interface with key stakeholders, understand their perspectives and craft communications strategies accordingly. As it relates to the growing influence of ...

Ahead of the American Society of Clinical Oncology (ASCO) 2025 annual meeting, Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers ...

This recommendation is unchanged from the 2017 ASCO Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer 3 and the 2021 joint Ontario Health (OH; Cancer Care Ontario)-ASCO Management ...

ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win. By Zoey Becker May 30, 2025 8:00am. ASCO 2025 Pfizer Eli Lilly BRAF. Pfizer isn’t ...

"ASCO is alarmed about significant proposed funding cuts to the NIH and NCI," Hudis said in the statement. "America became the global leader in medical research and innovation through deliberate ...

ASCO 2025 will feature the latest advancements in genitourinary cancer and melanoma treatment, focusing on the exciting developments in immunotherapy. Stay updated on the cutting-edge research and ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL).

The data presented at this ASCO meeting are from two multi-center Phase 1 and 2 clinical studies (registration no.: NCT05460767, NCT06081920) designed to evaluate the efficacy and safety of IBI363 ...